Introduction
============

The 31 kDa protein IL-33 belongs to the IL-1 family of cytokines ([@b1-ijmm-29-04-0530]) and was first described as a nuclear factor produced by high endothelial venule cells (NF-HEV) ([@b2-ijmm-29-04-0530]). Precursor IL-33 seems to function as a regulator/repressor of nuclear transcription ([@b3-ijmm-29-04-0530]). This nuclear function is associated with the homeodomain-like helix-turn-helix motif in the N-terminal part of IL-33, which mediates DNA binding. A transcriptional regulatory function of precursor IL-33 is further supported by the nuclear localization of IL-33 in HUVECs and IL-33-overexpressing cells, but also in LPS-stimulated murine astrocytes ([@b2-ijmm-29-04-0530]--[@b5-ijmm-29-04-0530]). After secretion, mature IL-33 (18 kD C-terminal fragment) acts as a pro-inflammatory cytokine via a receptor complex of ST2 and IL-1 receptor accessory protein (IL-1RacP). As a pro-inflammatory cytokine, mature IL-33 induces the production of TH~2~ cytokines by TH~2~-cells and the secretion of numerous cytokines by human and murine mast cells ([@b6-ijmm-29-04-0530],[@b7-ijmm-29-04-0530]). The biological effects of IL-33/ST2 are mediated by activation of the p38, ERK, JNK, and NF-κB signaling pathways ([@b1-ijmm-29-04-0530],[@b8-ijmm-29-04-0530]). However, it has been recently shown that processing of precursor IL-33 results in an inactivation, rather than an activation of IL-33 ([@b9-ijmm-29-04-0530]). In addition, precursor IL-33 activates NF-κB and induces IL-6 synthesis. Therefore, it has been proposed that IL-33 functions as an endogenous danger signal (alarmin) to alert cells of the innate immune system to tissue damage during trauma or infection ([@b9-ijmm-29-04-0530],[@b10-ijmm-29-04-0530]).

The IL-33/ST2 system is involved in numerous diseases and pathological conditions, e.g., fibroproliferative and cardiovascular diseases, asthma, and rheumatoid arthritis (RA) ([@b8-ijmm-29-04-0530]). An important role of IL-33 in the pathogenesis of RA is suggested by studies in the animal model of murine collagen-induced arthritis ([@b11-ijmm-29-04-0530]--[@b14-ijmm-29-04-0530]). Treatment of diseased animals with soluble ST2 fusion protein or a blocking anti-ST2 receptor reduced the disease severity compared to non-treated animals (e.g., reduction in synovial cellular infiltration, synovial hyperplasia, joint erosion and serum levels of pro-inflammatory cytokines); conversely, injection of IL-33 enhanced the signs of murine-collagen induced arthritis. Regarding human arthritis, IL-33 levels were elevated in the sera and synovial fluid of RA-patients and showed a positive correlation with the disease activity ([@b15-ijmm-29-04-0530]). IL-33 protein and also its receptor ST2 were detected in the lining layer and sublining of synovial membrane of RA patients ([@b12-ijmm-29-04-0530]). In addition to the strong expression of IL-33 in endothelial cells, fibroblasts and mononuclear inflammatory cells were identified as a potential source of IL-33 in the inflamed synovial membrane of RA patients ([@b3-ijmm-29-04-0530],[@b13-ijmm-29-04-0530]). IL-33 mRNA and protein expression was induced in RA synovial fibroblasts (RA-SFs) following TNF-α/IL-1β stimulation and IL-33 protein was mainly detected in the nucleus of RA-SFs ([@b12-ijmm-29-04-0530],[@b13-ijmm-29-04-0530]).

In addition to the role of mature IL-33 in the progression of RA ([@b14-ijmm-29-04-0530],[@b16-ijmm-29-04-0530]), the nuclear localization of pro-IL-33 in IL-1β/TNF-α stimulated cells may point to a regulatory function inside the cells, as it has been described for the other IL-1 family members IL-1α and IL-1F7b ([@b17-ijmm-29-04-0530],[@b18-ijmm-29-04-0530]). Therefore, the present study sought to analyze the involvement of IL-33 in TNF-α-induced pro-inflammatory or pro-destructive effector functions of RA-SFs.

Materials and methods
=====================

Patients, tissue digestion and cell culture
-------------------------------------------

Synovial tissue from RA-patients fulfilling the ARA criteria was obtained during open joint replacement/arthroscopic synovectomy from the Clinic of Orthopedics, Eisenberg, Germany ([@b19-ijmm-29-04-0530]). The study was approved by the Ethics Committee of the University of Jena, Germany, and patient informed consent was obtained.

RA synovial samples were digested, subsequently cultured for 7 days, and RA-SFs negatively isolated as previously described ([@b20-ijmm-29-04-0530],[@b21-ijmm-29-04-0530]). RA-SFs were cultured in the virtual absence of contaminating non-adherent cells and macrophages. Third-passage cells were used for all the experiments. Mycoplasma contamination of the cells was excluded by 4′-6-diamidino-2-phenylindole (DAPI) staining.

The stimulation of the cells with different concentrations of TNF-α (0.1 to 10.0 ng/ml; R&D Systems, Wiesbaden, Germany) was performed in DMEM/0.2% lactalbumin hydrolysate. For analysis of signal transduction pathways, cells were preincubated for 45 min with inhibitors of p38 MAPK (SB203580, 1 μM; Jena Biosciences, Jena, Germany), ERK (U0126, 1 μM, Axxora, Lörrach, Germany), JNK (SP600125, 20 μM, Jena Biosciences), NFκB (IκBK inhibitor peptide, cell-permeable, 50 μg/ml; Calbiochem, VWR, Darmstadt, Germany) ([@b22-ijmm-29-04-0530]), PKA (PKA inhibitor fragment 14--22, myristoylated trifluoroacetate salt, 10 μM, Sigma, Deisenhofen, Germany) ([@b23-ijmm-29-04-0530]) or PI3-kinase (wortmannin, 1 μM, Axxora), followed by TNF-α stimulation for 24 h. For analysis of the influence of different cytokines/growth factors on IL-33 synthesis, RA-SFs were stimulated with TNF-α, IL-18, PDGF-BB, TGF-β1 (10 ng/ml each), or IL-1β for 24 h (5 ng/ml; R&D Systems; Peprotech, London, UK). To analyze the influence of exogenous IL-33 on signal transduction and functional parameters of RA-SFs, cells were stimulated with 10 or 100 ng/ml recombinant human IL-33 (R&D Systems) for 15 min (signal transduction) or 24 h (protein secretion). Viability of the cells was assessed by ethidium bromide staining.

Analysis of the IL-33 protein expression and signal transduction by Western blotting
------------------------------------------------------------------------------------

Equal volumes of supernatants or 50 μg cellular protein were separated by 12% SDS-PAGE using a Laemmli buffer system as previously described ([@b24-ijmm-29-04-0530]). Primary anti-IL-33 antibody was obtained from R&D Systems. The band intensities were quantified using the software program Diana III luminescence imaging system (Raytest, Straubenhardt, Germany) and normalized to β-actin. Signal transduction in IL-33 and TNF-α stimulated RA-SFs was analyzed as previously described ([@b25-ijmm-29-04-0530]).

Overexpression of IL-33 in RA-SFs
---------------------------------

Overexpression of IL-33 in RA-SFs was performed using the ViraPower™ Lentiviral Expression System according to the manufacturer's instructions (Invitrogen, Karlsruhe, Germany). In brief, the coding sequence of IL-33 was cloned into the plenty6/V5 vector. For producing lentivirus, 296FT cells were transfected with the ViraPower™ packaging mix, the pLenti IL-33 expression plasmid, or the empty pLenti expression plasmid using Lipofectamine™ 2000 and Opti-MEM^®^ I medium. After 24 h, the medium was changed to complete culture medium according to the manufacturer's instructions (Invitrogen). Virus-containing supernatants were collected 72 h post-transfection, centrifuged to remove cell debris, and stored in aliquots at −80°C. For IL-33 overexpression, RA-SFs were transduced with the virus-containing supernatant in the presence of Polybrene™ (6 μg/ml; Sigma, Deisenhofen, Germany). After 24 h incubation, the virus-containing medium was replaced by DMEM/10% FCS and blasticidin for selection resulting in cells of passage 5. Overexpression of IL-33 was analyzed by RT-PCR and ELISA. As a control, RA-SFs were transduced with empty pLenty6/V5 vector.

Silencing of IL-33 in RA-SFs
----------------------------

Silencing of IL-33 in RA-SFs was performed by the siRNA technique using reverse transfection according to the manufacturer's instructions (Invitrogen). In brief, Stealth™ RNAi and Lipofectamine™ RNAiMAX (Invitrogen) were mixed in Opti-MEM^®^ I (Invitrogen) and incubated for 20 min at room temperature to allow complex formation. Subsequently, cells suspended in DMEM and 10% FCS without antibiotics were added and incubated for 24 h. Thereafter, cells were stimulated with 10 ng/ml TNF-α in DMEM and 0.2% lactalbumin hydrolysate for 24 h. Supernatants of the cells were collected for the analysis of cytokine and protease secretion. Cells were washed twice with ice-cold PBS and subsequently lysed in buffer for RNA-isolation (Macherey Nagel, Düren, Germany) or ice-cold buffer for protein extraction (50 mM Tris, 150 mM NaCl, EDTA, pH 7.4, containing 100 mM NP-40, 1 mM phenylmethylsulphonylfluoride, 1 mM Na~3~VO~4~, 2 μg/ml aprotinin, 2 μg/ml pepstatin, and 2 μg/ml leupeptin). For the analysis of IL-33 silencing, 35 μg of cellular protein were separated by 15% SDS-PAGE using a Laemmli buffer system. Transfection efficiency was analyzed using 10 nM Block-iT™ AlexaFluor^®^ Red Fluorescent Oligo (Invitrogen).

Immunohistochemistry for IL-33 in RA-SFs
----------------------------------------

For IL-33-immunohistochemistry in RA-SFs, 0.4×10^5^ cells/well (8-chamber slides) were allowed to adhere for 24 h, stimulated for 24 h with 10 ng/ml TNF-α, 5 ng/ml IL-1β, 10 ng/ml IL-18, 10 ng/ml PDGF-BB, or 10 ng/ml TGF-β1 in DMEM with 0.2% lactalbumin hydrolysate, followed by fixation with 3.7% paraformaldehyde in PBS for 15 min at room temperature (RT) and by neutralization with 50 mM NH~4~Cl in PBS for 5 min at RT. Fixed cells were permeabilized with PBS/0.1% Triton X-100 for 5 min at RT. To inactivate endogenous peroxidase, cells were incubated with 0.03% H~2~O~2~/PBS for 20 min. Thereafter, cells were incubated with primary antibody (clone Nessy-1, Axxora) in PBS/1% bovine serum albumin for 2 h at RT, washed 3 times for 5 min each with PBS/1% BSA, and incubated with horseradish-peroxidase-coupled goat anti-rabbit IgG (Dako, Hamburg, Germany) in PBS/1% BSA for 1 h at room temperature. Cells were washed thoroughly with PBS and stained with DAB.

Analysis of IL-33 mRNA expression and functional parameters by RT-PCR
---------------------------------------------------------------------

Total RNA was isolated from RA-SFs and reverse-transcribed as previously described ([@b26-ijmm-29-04-0530],[@b27-ijmm-29-04-0530]). mRNA expression for IL-33, IL-6, IL-8, MCP-1, MMP-1, MMP-3, TIMP-1, and the house-keeping gene aldolase was analyzed by real-time PCR using a RealPlex^®^ PCR machine (Eppendorf, Hamburg, Germany; ([@b26-ijmm-29-04-0530],[@b27-ijmm-29-04-0530]). The primer pairs and PCR conditions are presented in [Table I](#tI-ijmm-29-04-0530){ref-type="table"}. The relative concentrations of IL-33, IL-6, IL-8, MCP-1, MMP-1, MMP-3, and TIMP-1 mRNA in each sample were calculated by the RealPlex^®^ software using an external standard curve. Product specificity of the real-time PCR was confirmed by: i) melting curve analysis; ii) agarose gel electrophoresis; and iii) initial cycle sequencing of the PCR products.

Analysis of functional parameters in RA-SFs by ELISA
----------------------------------------------------

Proliferation was assessed by BrdU incorporation using a commercially available cell proliferation ELISA (Roche) as previously described ([@b25-ijmm-29-04-0530]). Human IL-6, IL-8, MCP-1, TIMP-1, and PGE~2~ were measured in diluted cell culture supernatants using commercially available ELISA kits (OptEIA™, BD Biosciences, Heidelberg, Germany; R&D Systems; GE Healthcare, Freiburg, Germany). Human MMP-1 and MMP-3 were measured in diluted cell culture supernatants as previously described ([@b27-ijmm-29-04-0530]). The resulting colour was read at 450 nm in microtiter plates spectrophotometer (Fluostar Optima, BMG LABTECH GmbH, Ortenberg, Germany).

Statistical analysis
--------------------

Data are presented as means ± standard error of the mean (SEM). The non-parametric Mann-Whitney U-test was applied to analyze differences between controls and individual stimuli, or among different stimuli (software program SPSS 10.0^TM^; SPSS Inc., Chicago, IL, USA). Significant differences were accepted for P≤0.05.

Results
=======

Influence of TNF-α on the expression of IL-33 mRNA and protein in RA-SFs
------------------------------------------------------------------------

TNF-α significantly and dose-dependently induced the expression of IL-33 mRNA in RA-SFs ([Fig. 1A](#f1-ijmm-29-04-0530){ref-type="fig"}). The expression of IL-33 was significantly induced starting at the lowest concentration of TNF-α (0.1 ng/ml; [Fig. 1A](#f1-ijmm-29-04-0530){ref-type="fig"}) and further augmented by higher concentrations thereof (plateau at 5.0 or 10 ng/ml TNF-α; [Fig. 1A](#f1-ijmm-29-04-0530){ref-type="fig"}). TNF-α also significantly induced IL-33 protein in RA-SFs ([Fig. 1B](#f1-ijmm-29-04-0530){ref-type="fig"}); the production of IL-33 reached a plateau at the lowest concentration of TNF-α (0.1 ng/ml; [Fig. 1B](#f1-ijmm-29-04-0530){ref-type="fig"}).

Non-stimulated RA-SFs showed a weak staining for IL-33 ([Fig. 1C](#f1-ijmm-29-04-0530){ref-type="fig"}). However, following stimulation with TNF-α RA-SFs showed a strong positive staining predominantly localized in the nucleus ([Fig. 1C](#f1-ijmm-29-04-0530){ref-type="fig"}). To analyze whether TNF-α-induced IL-33 protein is secreted, IL-33 protein was analyzed in the supernatants and cell lysates of RA-SFs following TNF-α stimulation. It was clearly shown that IL-33 was not secreted by RA-SFs, but remained exclusively in the cell lysates ([Fig. 1D](#f1-ijmm-29-04-0530){ref-type="fig"}).

TNF-α-induced IL-33 mRNA expression in RA-SFs was significantly reduced by inhibition of p38 MAPK (SB203580), ERK (U0126), NFκB (IκBK inhibitor peptide), and PKA (PKA inhibitor fragment 14--22) ([Fig. 2A](#f2-ijmm-29-04-0530){ref-type="fig"}). Inhibition of JNK (SP600125) and PI3-kinase (wortmannin) had no significant influence on the TNF-α-induced IL-33 mRNA expression. However, at the protein level inhibition of p38 significantly reduced TNF-α-induced IL-33 ([Fig. 2B](#f2-ijmm-29-04-0530){ref-type="fig"}). In contrast, inhibition of the NFκB pathway and PI3-kinase significantly induced IL-33 protein in RA-SFs. No significant viability differences were observed between non-stimulated cells (control) and TNF-α-stimulated cells with/without inhibitors (viability in all cases: \>97%; data not shown).

Effects of IL-33 overexpression on the TNF-α-induced functions of RA-SFs
------------------------------------------------------------------------

Lentiviral overexpression of IL-33 mRNA significantly augmented the TNF-α induced IL-33 mRNA and protein expression in RA-SFs ([Fig. 3A and B](#f3-ijmm-29-04-0530){ref-type="fig"}).

TNF-α significantly downregulated the proliferation of RA-SFs (data not shown) Overexpression of IL-33 further augmented the TNF-α induced downregulation of RA-SFs proliferation ([Fig. 3C](#f3-ijmm-29-04-0530){ref-type="fig"}). The TNF-α-induced PGE~2~ secretion in RA-SFs, in contrast, is further enhanced by IL-33 overexpression ([Fig. 3D](#f3-ijmm-29-04-0530){ref-type="fig"}).

At the mRNA level, overexpression of IL-33 significantly increased TNF-α-induced IL-6, IL-8, and MMP-3 in RA-SFs ([Fig. 4](#f4-ijmm-29-04-0530){ref-type="fig"}; shown as relative and absolute values). However, at the protein level, overexpression of IL-33 significantly induced the secretion of IL-6, IL-8, MCP-1, MMP-1, and MMP-3 ([Fig. 4](#f4-ijmm-29-04-0530){ref-type="fig"}). Overexpression of IL-33 did not significantly influence TIMP-1 expression at the mRNA or protein levels ([Fig. 4B](#f4-ijmm-29-04-0530){ref-type="fig"}).

Effects of IL-33 silencing on the TNF-α-induced functions of RA-SFs
-------------------------------------------------------------------

Silencing of IL-33 significantly reduced the TNF-α-induced IL-33 mRNA and protein expression in RA-SFs ([Fig. 5A and B](#f5-ijmm-29-04-0530){ref-type="fig"}). Transfection efficiency was greater than 85% using Block-iT™ AlexaFluor^®^ Red Fluorescent Oligo (85.4% ±2.7 positive cells). In addition, immunohistochemical analysis of IL-33 siRNA showed that IL-33 siRNA abolished the TNF-α-induced nuclear translocation of IL-33 ([Fig. 5C](#f5-ijmm-29-04-0530){ref-type="fig"}). The viability of the cells was not significantly influenced by silencing of IL-33 (viability, \>97%; data not shown). The TNF-α-regulated proliferation of RA-SFs was not significantly influenced by IL-33 silencing ([Fig. 5D](#f5-ijmm-29-04-0530){ref-type="fig"}). In contrast, silencing of IL-33 significantly reduced the TNF-α-induced PGE~2~ secretion ([Fig. 5E](#f5-ijmm-29-04-0530){ref-type="fig"}).

Silencing of IL-33 significantly reduced the TNF-α induced synthesis of IL-6, IL-8, and MCP-1 in RA-SFs at the mRNA and protein levels ([Fig. 6A](#f6-ijmm-29-04-0530){ref-type="fig"}). In contrast to the pro-inflammatory mediators, the synthesis of the pro-destructive mediators was not significantly influenced by IL-33 silencing in RA-SFs ([Fig. 6B](#f6-ijmm-29-04-0530){ref-type="fig"}).

Influence of different cytokines and growth factors on the IL-33 protein expression in RA-SFs
---------------------------------------------------------------------------------------------

In addition to TNF-α, the pro-inflammatory cytokine IL-1β significantly induced IL-33 synthesis (fold-induction compared to control cells: TNF-α, 7.1-fold; IL-1β, 15.7-fold; [Fig. 7A](#f7-ijmm-29-04-0530){ref-type="fig"}). In contrast, the pro-inflammatory cytokine IL-18 or the growth factors PDGF-BB and TGF-β1 had no significant influence on IL-33 synthesis. In agreement with these data, nuclear translocation of IL-33 was solely observed in TNF-α or IL-1β-stimulated cells ([Fig. 7B](#f7-ijmm-29-04-0530){ref-type="fig"}; results for IL-1β and PDGF-BB are shown).

Influence of exogenous IL-33 on signal transduction and protein expression of pro-inflammatory and pro-destructive mediators in RA-SFs
--------------------------------------------------------------------------------------------------------------------------------------

External IL-33 stimulation (10 or 100 ng/ml) of RA-SFs did not induce a significant increase in the phosphorylation of p38, ERK, or JNK ([Fig. 8A-C](#f8-ijmm-29-04-0530){ref-type="fig"}). Also, no significant decrease of IκBα was observed following IL-33 stimulation of RA-SFs ([Fig. 8D](#f8-ijmm-29-04-0530){ref-type="fig"}). Accordingly, IL-33 stimulation did not significantly induce the protein secretion of IL-6, MCP-1, MMP-1, and MMP-3 ([Fig. 9](#f9-ijmm-29-04-0530){ref-type="fig"}). In all cases, TNF-α induced a significant activation of the analyzed signaling pathways and a significant increase of the secretion of pro-inflammatory and pro-destructive mediators ([Figs. 8](#f8-ijmm-29-04-0530){ref-type="fig"} and [9](#f9-ijmm-29-04-0530){ref-type="fig"}).

Discussion
==========

The present study demonstrates for the first time, that i) TNF-α induced IL-33 expression is regulated via p38; ii) the pro-inflammatory cytokines TNF-α and IL-1β are potent inducers of IL-33 synthesis; and iii) IL-33 is involved in the regulation of TNF-α-induced synthesis of pro-inflammatory and pro-destructive molecules. Therefore, IL-33 is a critical regulator of TNF-α-induced functions in RA-SFs, pointing to a central role of this cytokine in the perpetuation of pro-inflammatory and pro-destructive processes in RA and other inflammatory and degenerative diseases.

In agreement with previously published data, the present study shows that IL-33 mRNA/protein expression is induced in RA-SFs following TNF-α stimulation ([@b12-ijmm-29-04-0530],[@b13-ijmm-29-04-0530]). Interestingly, IL-33 was only detected in the nucleus of TNF-α-stimulated RA-SFs, but not or only barely in the supernatant of stimulated RA-SFs \[present publication, unpublished data and ([@b13-ijmm-29-04-0530])\]. This nuclear localization has also been observed in HUVECs and glia cells ([@b2-ijmm-29-04-0530],[@b4-ijmm-29-04-0530],[@b5-ijmm-29-04-0530]) and supports the proposed function of IL-33 as a transcriptional regulator ([@b3-ijmm-29-04-0530]). Nuclear translocation of IL-33 following TNF-α/IL-1β stimulation of RA-SFs therefore indicates that IL-33 may function as a transcriptional regulator rather than as an external cytokine. This view is further supported by the observation that the long signaling ST2 receptor is not expressed on the cells ([@b13-ijmm-29-04-0530]). In addition, RA-SFs do not respond to IL-33 stimulation with an activation of signal transduction molecules (p38, Erk, JNK, and NF-κB) or IL-6, MCP-1, MMP-1, and MMP-3 expression (present publication; ([@b13-ijmm-29-04-0530]). The incapability of RA-SFs to secrete mature IL-33 may be based on an inability of the cells to efficiently cleave pro-IL-33. Indeed, IL-1α, another member of the IL-1 family sharing several properties with IL-33, is only cleaved and secreted by monocytes and macrophage cell lines, but not by fibroblast cell lines ([@b28-ijmm-29-04-0530],[@b29-ijmm-29-04-0530]). In addition, only detergent-damaged RA-SFs release the 30 kDa IL-33 precursor into the supernatant ([@b15-ijmm-29-04-0530]) further supporting the view that IL-33 is not actively secreted by RA-SFs.

Currently nothing is known about the signaling pathways involved in the TNF-α-induced IL-33 synthesis in RA-SFs. The present study shows for the first time that TNF-α-induced IL-33 mRNA expression is mainly regulated via p38, underlining its central pro-inflammatory role and identifying IL-33 as a new potential target for anti-rheumatic therapy with inhibitors of this signaling pathway.

IL-33 synthesis is differentially induced by cytokines and growth factors in RA-SFs. The pro-inflammatory cytokines TNF-α and, in particular, IL-1β strongly induce IL-33 synthesis. In contrast, the pro-inflammatory cytokine IL-18 or the growth factors PDGF-BB and TGF-β1 did not significantly stimulate IL-33 synthesis. In addition, a nuclear localization of IL-33 was only observed in IL-1β or TNF-α-stimulated cells, further emphasizing the prominent role of these 2 cytokines in regulating the expression/functional effects of IL-33. The induction of IL-33 by IL-1β and TNF-α also further underlines the central role of these cytokines in the pathogenesis of RA for the induction/regulation of disease-relevant molecules ([@b30-ijmm-29-04-0530]). Strong induction of IL-33 by IL-1β is in good agreement with previously published data in CNS glial cultures showing that IL-1β induces IL-33 more strongly than pathogen-associated molecular patterns, e.g., dsRNA or LPS ([@b4-ijmm-29-04-0530]). In contrast, superconfluent HUVECs responded with a down-regulation of IL-33 protein following IL-1β or TNF-α stimulation ([@b5-ijmm-29-04-0530]). Therefore, the regulation of IL-33 by the pro-inflammatory cytokines IL-1β and TNF-α seems to be cell type- and/or pathway-specific.

This study shows for the first time that IL-33 is involved in the regulation of TNF-α-induced functions in RA-SFs. Overexpression of IL-33 enhanced the TNF-α-induced reduction of proliferation in RA-SFs. Interestingly, the TNF-α-mediated downregulation of proliferation is solely dependent on the p38 signal pathway in RA-SFs ([@b25-ijmm-29-04-0530]). This is in good agreement with the regulation of TNF-α-induced IL-33 synthesis via p38 ([Fig. 2](#f2-ijmm-29-04-0530){ref-type="fig"}) suggesting a downregulation of RA-SFs proliferation by TNF-α via a p38-IL-33 axis. The TNF-α/IL-33-induced downregulation of RA-SFs proliferation is in sharp contrast with previous reports suggesting induction of SFs proliferation by TNF-α ([@b31-ijmm-29-04-0530],[@b32-ijmm-29-04-0530]). This discrepancy may be explained by the usage of differentially purified RA-SFs (anti-CD14-purified cells in the present publication vs. cells purified by passaging) and differential usage of serum-free or serum-containing medium.

Overexpression of IL-33 further augmented TNF-α-induced pro-inflammatory and pro-destructive functions in RA-SFs. Although this result was generally confirmed by IL-33 silencing, TNF-α-induced pro-destructive mediators were less strongly downregulated (MMP-1, MMP-3, TIMP-1). The difference in the effects of IL-33 overexpression and silencing on the regulation of TNF-α-induced pro-destructive functions may be based on the involvement of additional signaling pathways, e.g. p38 and NFκB ([@b25-ijmm-29-04-0530],[@b33-ijmm-29-04-0530]). In fact, the inhibition/silencing of one signaling molecule can increase the activity of other signaling pathways influencing cell functions ([@b34-ijmm-29-04-0530]).

The present data indicate that IL-33 has an enhancing effect on TNF-α-induced pro-inflammatory and pro-destructive functions in RA-SFs. This is in apparent contrast to the initially proposed function of IL-33 as a transcriptional repressor ([@b3-ijmm-29-04-0530]). However, the evidence for this function of IL-33 is predominantly based on *in vitro* assays using reporter vectors exclusively driven by multiple galactose 4 binding sites ([@b3-ijmm-29-04-0530],[@b35-ijmm-29-04-0530]). Also, there was no influence on the expression of selected genes by IL-33 overexpression or silencing in HUVECs ([@b5-ijmm-29-04-0530],[@b35-ijmm-29-04-0530]). In addition, it has been proposed that IL-33 may function as a potentiator of gene expression by decreasing the local concentration of transcriptional repressors on specific promoters and thereby allowing activators to bind more efficiently ([@b3-ijmm-29-04-0530]). Thus, the precise transcriptional influence of IL-33 on the expression of individual genes in specific cell types will have to be further analyzed.

In the present study, overexpression and silencing of IL-33 influenced mRNA and protein expression of selected target genes to a comparable degree. This indicates that in RA-SFs IL-33 exerts its enhancing influence at the transcriptional level, either exclusively or in combination with other mechanisms. This is supported by recent data showing that a short motif of IL-33 binds with to the acidic pocket formed by the histone H2A-H2B dimer at the surface of the nucleosome, a region important for chromatin compaction and subsequent transcriptional activity ([@b35-ijmm-29-04-0530]) . However, the chromatin-binding motif of IL-33 induced a higher order structure of chromatin and mutations of the motif reduced its transcriptional repressor properties. It therefore remains the subject of future studies how the differential influence of IL-33 on gene transcription can be mechanistically explained.

The regulation of pro-inflammatory mediators by nuclear IL-33 is in good agreement with previously published data using inflammatory cells. Stimulation of these cells with IL-33 induced the synthesis of several pro-inflammatory mediators, e.g., IL-6, IL-8, and MCP-1 ([@b7-ijmm-29-04-0530],[@b36-ijmm-29-04-0530],[@b37-ijmm-29-04-0530]). However, in contrast to RA-SFs, these cells express ST2 and therefore responded to external IL-33 stimulation ([@b37-ijmm-29-04-0530],[@b38-ijmm-29-04-0530]). Thus, pro-inflammatory mediators may be enhanced by nuclear IL-33 in cells not expressing the IL-33 receptor ST2.

Interestingly, lentiviral IL-33 overexpression enhanced IL-33 mRNA and protein expression only in TNF-α-stimulated RA-SFs, pointing to a stabilization of IL-33 by TNF-α. A similar effect has been reported for another member of the IL-1 family, IL-1F7b ([@b39-ijmm-29-04-0530]). In agreement with our observation for IL-33, IL-1F7b overexpressing RAW264.7 cells showed high intracellular IL-1F7b level only after LPS stimulation. Therefore, the mRNA of different members of the IL-1 family may be stabilized by pro-inflammatory stimuli, resulting in an increased protein synthesis.

The present study identifies IL-33 as a critical regulator of TNF-α-induced pro-inflammatory and pro-destructive functions in RA-SFs (likely at the transcriptional level) and raises interesting questions concerning cell type- or gene-specific effects and/or the exact molecular mechanism of gene regulation.
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![Influence of TNF-α on IL-33 mRNA and protein expression in RA-SFs and cellular localization of IL-33 in TNF-α stimulated RA-SFs. (A and B) RA-SFs (n=5) were stimulated with TNF-α (0.1, 0.5, 1.0, 5.0 or 10.0 ng/ml). The mRNA expression of IL-33 was analyzed by (A) RT-PCR, the protein expression by (B) ELISA. RA-SFs (n=4) were stimulated for 24 h with 10 ng/ml TNF-α. (C) Thereafter, IL-33 was detected in the cells by immunohistochemistry using a specific antibody against IL-33 or (D) in supernatants and cell lysates by Western blotting; conc, concentrated supernatants. Representative results are shown in (C and D). ^+^P≤0.05 vs.control;^\*^P≤0.05 vs. 0.1 ng/ml TNF-α; ^§^P≤0.05 vs. 0.5 ng/ml TNF-α by the Mann-Whitney U-test. Bars indicate means ± SEM vs. control.](IJMM-29-04-0530-g00){#f1-ijmm-29-04-0530}

![Signal transduction pathways involved in the TNF-α induced IL-33 expression in RA-SFs. RA-SFs (mRNA n=5; protein n=3) were preincubated for 45 min with the individual inhibitors as indicated followed by stimulation with 10 ng/ml TNF-α for 24 h. The mRNA expression of IL-33 was analyzed by RT-PCR (A) and protein expression by ELISA (B). ^+^P≤0.05 vs. control; °P≤0.05 vs. 10 ng/ml TNF-α without inhibitors by the Mann-Whitney U-test. Bars indicate means ± SEM.](IJMM-29-04-0530-g01){#f2-ijmm-29-04-0530}

![Lentiviral overexpression of IL-33 and influence of IL-33 overexpression on proliferation and PGE~2~ secretion in TNF-α-stimulated RA-SFs. RA-SFs (n=3) were transduced with empty plenty6/V5 vector or IL-33 plenty6/V5 vector and selected with blasticidin. IL-33 overexpression was analyzed following TNF-α stimulation using (A) RT-PCR or (B) ELISA. Proliferation of the cells was assessed by BrdU incorporation (C) and PGE~2~ secretion by ELISA (D). ^+^P≤0.05 Mann-Whitney U-test vs. control (cells without vector). Bars indicate means ± SEM.](IJMM-29-04-0530-g02){#f3-ijmm-29-04-0530}

![Effects of IL-33 overexpression on the mRNA and protein expression of pro-inflammatory and pro-destructive mediators in TNF-α stimulated RA-SFs. RA-SFs (n=3) were stimulated with TNF-α (10 ng/ml) for 24 h. mRNA and protein expression of (A) the pro-inflammatory mediators IL-6, IL-8, and MCP-1, and (B) the pro-destructive mediators MMP-1, MMP-3, and TIMP-1 were analyzed by real-time PCR or ELISA. ^+^P≤0.05 Mann-Whitney U-test vs. control vector. Bars indicate means ± SEM.](IJMM-29-04-0530-g03){#f4-ijmm-29-04-0530}

![Silencing of IL-33 and influence of IL-33 silencing on proliferation and PGE~2~ secretion in TNF-α-stimulated RA-SFs. RA-SFs (mRNA n=4; protein n=3) were preincubated for 24 h with 10 nM control siRNA or specific IL-33 siRNA followed by TNF-α stimulation (10 ng/ml) for 24 h. IL-33 expression was analyzed by real-time PCR (A) and Western blotting (B) or by immunohistochemistry using a specific IL-33 antibody (B; in Fig. B and C a representative result is shown). Proliferation of the cells was assessed by BrdU incorporation (D) and PGE~2~ secretion by ELISA (E). ^+^P≤0.05 Mann-Whitney U-test vs. control siRNA. Bars indicate means ± SEM.](IJMM-29-04-0530-g04){#f5-ijmm-29-04-0530}

![Effects of IL-33 silencing on the mRNA and protein expression of pro-inflammatory and pro-destructive mediators in TNF-α stimulated RA-SFs. RA-SFs (n=5) were preincubated for 24 h with 10 nM control siRNA or specific IL-33 siRNA followed by TNF-α stimulation (10 ng/ml) for 24 h. mRNA and protein expression of (A) the pro-inflammatory mediators IL-6, IL-8 and MCP-1, and (B) the pro-destructive mediators MMP-1, MMP-3, and TIMP-1 were analyzed by real-time PCR or ELISA. ^+^P≤0.05 Mann-Whitney U-test vs. control siRNA. Bars indicate means ± SEM.](IJMM-29-04-0530-g05){#f6-ijmm-29-04-0530}

![Influence of selected cytokines and growth factors on the IL-33 synthesis in RA-SFs. RA-SFs (n=4) were stimulated for 24 h with TNF-α, IL-1β, IL-18, PDGF-BB or TGF-1β (concentrations as indicated in the figure). Synthesis of IL-33 in the cell lysates was analyzed by ELISA (A) or in cells by immunohistochemistry using a specific antibody against IL-33. (B) Representative results are shown. ^+^P≤0.05 Mann-Whitney U-test vs. control. Bars indicate means ± SEM.](IJMM-29-04-0530-g06){#f7-ijmm-29-04-0530}

![Influence of exogenous IL-33 on the signal transduction in RA-SFs. RA-SFs (n=3) were stimulated with IL-33 (10 or 100 ng/ml) or as a positive control with TNF-α (10 ng/ml) for 15 min. Activation of p38, JNK, ERK, and IκBα was analyzed by Western blotting. ^+^P≤0.05 Mann-Whitney U-test vs. control. Bars indicate means ± SEM.](IJMM-29-04-0530-g07){#f8-ijmm-29-04-0530}

![Influence of exogenous IL-33 on the protein expression of pro-inflammatory and pro-destructive mediators in RA-SFs. RA-SFs (n=4) were stimulated with IL-33 (10 or 100 ng/ml) or TNF-α (10 ng/ml) for 24 h. Protein expression of IL-6 (A), MCP-1 (B), MMP-1 (C), and MMP-3 (D) was analyzed by ELISA. ^+^P≤0.05 Mann-Whitney U-test vs. control siRNA. Bars indicate means ± SEM.](IJMM-29-04-0530-g08){#f9-ijmm-29-04-0530}

###### 

Primer sequences and annealing temperatures used in RT-PCR.

  Gene                                        Primer sequence                Annealing temperature, °C   Melting temperature, °C
  ----------- ------------------------------- ------------------------------ --------------------------- -------------------------
  Aldolase    Sense                           5-tcatcctcttccatgagacactct-3   58                          82
  Antisense   5-attctgctggcagatactggcataa-3                                                              
  IL-33       Sense                           5-cacccctcaaatgaatcagg-3       60                          84
  Antisense   5-ggagctccacagagtgttcc-3                                                                   
  IL-6        Sense                           5-atgaactccttctccacaagcg-3     62                          84
  Antisense   5-ctcctttctcagggctgag-3                                                                    
  IL-8        Sense                           5-gccaagagaatatccgaact-3       60                          78
  Antisense   5-aggcacagtggaacaaggacttgt-3                                                               
  MCP-1       Sense                           5-cagccagatgcaatcaatgcc-3      60                          82
  Antisense   5-tggaatcctgaacccacttct-3                                                                  
  MMP-1       Sense                           5-gacctggaggaaatcttgc-3        58                          81
  Antisense   5-gttagcttactgtcacacgc-3                                                                   
  MMP-3       Sense                           5-gaacaatggacaaaggatacaaca-3   58                          81
  Antisense   5-aagattgatgctgtttttgaagaa-3                                                               
  TIMP-1      Sense                           5-cttctggcatcctgttgttg-3       60                          82
  Antisense   5-agaaggccgtctgtgggt-3                                                                     
